Adaptive Learning to Improve Individualized Management of Type 2 Diabetes (T2D)
Released On
May 31, 2023
Expires On
May 31, 2024
Media Type
Internet
Completion Time
75 minutes
Specialty
Endocrinology, Primary Care
Topic(s)
Diabetes, Nutrition, Obesity
This activity is provided by the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Lilly.
Credit Available
- Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)™
Target Audience
This activity is intended for physicians and advanced practice providers in the primary care setting who treat diverse patients with type 2 diabetes mellitus (T2DM).
Program Overview
As a primary care provider, you play a critical role in the management of patients with type 2 diabetes. ACHL AdaptED® offers a unique experience designed to meet the needs of busy clinicians seeking to enhance their expertise in this area. Our adaptive learning platform allows you to tailor your educational experience to match your specific learning goals and knowledge gaps. This activity has you covered whether you're looking to deepen your understanding of the latest treatment options, improve your ability to manage comorbidities, or simply stay up-to-date on the latest research.
Featuring expert faculty with extensive experience in managing type 2 diabetes, the program delivers practical insights and strategies you can apply in your practice immediately. Don't miss this opportunity to take your skills to the next level and provide the best possible care for your patients. Access the ACHL AdaptED® platform today.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the benefits of earlier treatment intensification and weight loss in achieving established goals for glycemic control
- Summarize the latest research on the role of incretin-based therapies in patients with T2DM, obesity, and obesity-related comorbidities
- Optimize strategies to achieve sustained weight loss in T2DM patients based on varied patient characteristics and targets
- Formulate individualized management strategies to reduce long-term complications in patients with T2DMOUR
Faculty
Kathleen Dungan, MD
Professor of Internal Medicine
Division of Endocrinology, Diabetes & Metabolism
The Ohio State University
Columbus, OH
Jennifer B. Green, MD
Professor of Medicine Division of Endocrinology, Metabolism and Nutrition
Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credit(s) through their reciprocity agreements.
Disclosures of Conflicts of Interest
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
- Kathleen Dungan, MD
- Consultant (occasional): Dexcom, Eli Lilly
- Grant/Research Support: Abbott, Dexcom, Insulet, Sanofi, Viacyte
- Jennifer B. Green, MD
- Consultant (occasional): Anji, AstraZeneca, Boehringer Ingelheim/Lilly, NovoNordisk, Pfizer, Sanofi, Valo, Vertex
- Consultant (retained): Bayer, Merck
- Grant/Research Support: Boehringer Ingelheim/Lilly, Merck, Roche
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Amylin receptor agonists and efpeglenatide are investigational and are not approved for the treatment of obesity and/or type 2 diabetes; tirzepatide and oral semaglutide are not indicated for cardiovascular risk reduction in patients with type 2 diabetes or for the treatment of obesity; bempedoic acid is not indicated for cardiovascular risk reduction in statin-intolerant patients with or at high risk for atherosclerotic cardiovascular disease; GLP-1 receptor agonists other than liraglutide and semaglutide, SGLT2 inhibitors, metformin, and pramlintide are not indicated for the treatment of obesity.
Instructions for Participation and Credit
To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Disclaimer
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information
For CME questions, please contact Laurie Novoryta at Lnovoryta@achlcme.org.